[Eosinophilia-myalgia syndrome].
The following is an outline of one typical case of chronic eosinophilia-myalgia syndrome (EMS). In 1987 a 62-year-old woman began taking L-tryptophan, 1.5 g nightly, due to sleeping difficulty. During the months preceding the appearance of EMS she continued to take L-tryptophan, derived from the biosynthetic production of the Japanese manufacturer "Showa Denko". She has suffered increasingly from severe myalgia and a proximal muscle weakness since July of 1989. In November, 1989 her white blood cell count measured 12.1 X 10(9)/l with 3.6 X 10(9) eosinophil cells/l. The bone marrow exhibited an increased granulopoesis and an extreme increase in the amount of eosinophil cells. The muscle biopsy specimen indicated an inflammation with perivascular distribution. The eosinophil cell count of the blood was quickly normalized via the introduction of prednisone over a short period. In the absence of further immunosuppressive therapy a slow improvement can be seen in the myalgia and in her general condition. Since the beginning of 1990 there has been a slow development of hyperpigmented scleroderma-like skin changes with distal distribution.
Sieb
J P
JP
Neurologische Klinik, Universität Bonn.
Scholten
T
T
Beyenburg
S
S
Uerlich
M
M
Hebborn
G
G
D001706:Biopsy; D004802:Eosinophilia / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009220:Myositis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D009460:Neurologic Examination; D012867:Skin / Q000473:pathology; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D014364:Tryptophan / Q000008:administration & dosage / Q000009:adverse effects*
D014364:Tryptophan
Eosinophilie-Myalgie-Syndrom.